Lilly announces negative results in schizophrenia drug trial

INDIANAPOLIS — A clinical trial of a drug for schizophrenia did not yield the desired results, the drug's developer said.



Eli Lilly announced results of the H8Y-MC-HBBM study of pomaglumetad methionil, for patients with acute exacerbation of schizophrenia. The company said results did not show the drug produced a significantly different effect from the placebo.



"Unfortunately, negative studies are common in the field of psychiatry and a reality of biopharmaceutical innovation," Lilly Research Labs EVP science and technology and president Jan Lundberg said. "Despite all of the advances, the need for new and better treatments for those suffering with mental illnesses is among the most urgent in medicine."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.